Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Phase 3b open-label design, 751 adults with obesity but without T2D, randomized 1:1 to max tolerated dose of tirzepatide (10 or 15 mg) or max tolerated dose of semaglutide (1.7 or 2.4 mg) for 72 weeks, both on top of behavioral support
This program is crafted to combat chronic diseases, reduce healthcare expenditures, and elevate overall well-being.
Theres always a risk that symptoms could worsen if the treatment doesnt provide adequate control
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo K
US$ 26.25
US$ 26.62
US$ 27.20
US$ 28.24
US$ 24.44
US$ 21.31
US$ 27.00
US$ 22.39
US$ 20.21
US$ 29.75
US$ 29.00
US$ 20.75
US$ 20.27
US$ 24.23
